0SGC Stock Overview A biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Arbutus Biopharma Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Arbutus Biopharma Historical stock prices Current Share Price US$3.44 52 Week High US$4.68 52 Week Low US$2.24 Beta 1.78 1 Month Change -6.81% 3 Month Change -8.42% 1 Year Change 38.94% 3 Year Change -2.03% 5 Year Change n/a Change since IPO -5.81%
Recent News & Updates Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.12 loss in 3Q 2023) Nov 07
Arbutus Biopharma Corporation to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2023) Aug 02
Arbutus Biopharma Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial Jun 08 See more updates Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.12 loss in 3Q 2023) Nov 07
Arbutus Biopharma Corporation to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2023) Aug 02
Arbutus Biopharma Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial Jun 08
Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201) Jun 06
Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma May 21
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders May 18 Whitefort Capital Management Engages with Arbutus Biopharma May 10
New major risk - Revenue and earnings growth May 04
First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 1Q 2023) May 03
Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024 May 03
Arbutus Biopharma Corporation to Report Q1, 2024 Results on May 02, 2024 Apr 20
Arbutus Biopharma Corporation, Annual General Meeting, May 22, 2024 Apr 11
Full year 2023 earnings released: US$0.44 loss per share (vs US$0.46 loss in FY 2022) Mar 01
Arbutus Biopharma Corporation to Report Q4, 2023 Results on Feb 29, 2024 Feb 16
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline Jan 09
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD Nov 11 Arbutus Biopharma Corporation Announces CEO Changes
Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2022) Nov 08
Arbutus Biopharma Corporation to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
New minor risk - Share price stability Oct 11
Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101 Sep 12
Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.095 loss in 2Q 2022) Aug 04
Arbutus Biopharma Corporation to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors Jul 13
Arbutus Biopharma Corporation Appoints Two New Executives Jul 12
Arbutus Biopharma Corporation Appoints Two New Executives Jul 11
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody Jun 22
Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023 Jun 07
First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.11 loss in 1Q 2022) May 05
Full year 2022 earnings released: US$0.46 loss per share (vs US$0.83 loss in FY 2021) Mar 04
Arbutus Biopharma Corporation Announces Resignation of Tram Tran from the Board of Directors, Effective on February 26, 2023 Jan 28
Arbutus Biopharma Corporation to Report Q4, 2022 Results on Mar 02, 2023 Jan 18
Arbutus Biopharma Corporation Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection Dec 15
Insufficient new directors Nov 17
Arbutus Biopharma Corporation Appoints Mike Mcelhaugh as Chief Operating Officer, Effective as of November 1, 2022 Oct 26
Arbutus Biopharma Corporation Announces Resignation of Gaston Picchio as Chief Development Officer Oct 01
Arbutus Biopharma Corporation to Report Q3, 2022 Results on Nov 03, 2022 Sep 27
Second quarter 2022 earnings released: US$0.095 loss per share (vs US$0.23 loss in 2Q 2021) Aug 05
Arbutus Biopharma Corporation to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with Ab-729 and Capsid Inhibitor Jul 21
Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EASL International Liver Congress™ 2022 and Provides Ab-836 Clinical Update Jun 26
Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus Jun 07
Insufficient new directors Jun 02
First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2021) May 06
Arbutus Biopharma Corporation to Report Q1, 2022 Results on May 05, 2022 Apr 22
Arbutus Biopharma Corporation, Annual General Meeting, May 25, 2022 Apr 12
Arbutus Provides Pipeline Updates Mar 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 04
Arbutus Biopharma Corporation to Report Q4, 2021 Results on Mar 03, 2022 Feb 18
Antios Therapeutics and Arbutus Biopharma Announces First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection Dec 15
Arbutus Biopharma Corporation announced that it expects to receive $14.999999 million in funding from Qilu Pharmaceutical Co., Ltd. Dec 14
Arbutus Biopharma Corporation Announces Preliminary Data from its On-Going Phase 1A/1B Clinical Trial Demonstrating That its Next Generation Capsid Inhibitor, AB-836 Dec 03
Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.27 loss in 3Q 2020) Nov 06
Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.24 loss in 2Q 2020) Aug 06
Arbutus Biopharma Corporation Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June Jun 03
First quarter 2021 earnings released: US$0.21 loss per share (vs US$0.25 loss in 1Q 2020) May 06
Arbutus Biopharma Corporation Receives Regulatory Approval to Initiate Phase 1a/1b Clinical Trial with AB-836, its Proprietary Oral Capsid Inhibitor for the Treatment of HBV Infection Mar 17
Arbutus Biopharma Corporation, Annual General Meeting, May 26, 2021 Mar 10
Full year 2020 earnings released: US$1.00 loss per share (vs US$2.89 loss in FY 2019) Mar 07
Revenue beats expectations Mar 07
Assembly Biosciences, Inc. and Arbutus Biopharma Corporation Announce Initiation of Phase 2 Clinical Trial of Assembly Bio's Investigational Hepatitis B Virus Core Inhibitor Candidate Feb 27
Arbutus Biopharma Corporation to Report Q4, 2020 Results on Mar 04, 2021 Feb 23 Shareholder Returns 0SGC GB Biotechs GB Market 7D 8.2% 2.7% 0.8% 1Y 38.9% -24.0% 4.4%
See full shareholder returns
Return vs Market: 0SGC exceeded the UK Market which returned 4.4% over the past year.
Price Volatility Is 0SGC's price volatile compared to industry and market? 0SGC volatility 0SGC Average Weekly Movement 5.3% Biotechs Industry Average Movement 9.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: 0SGC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0SGC's weekly volatility (5%) has been stable over the past year.
About the Company Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Show more Arbutus Biopharma Corporation Fundamentals Summary How do Arbutus Biopharma's earnings and revenue compare to its market cap? 0SGC fundamental statistics Market cap US$648.06m Earnings (TTM ) -US$76.70m Revenue (TTM ) US$6.74m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0SGC income statement (TTM ) Revenue US$6.74m Cost of Revenue US$62.79m Gross Profit -US$56.05m Other Expenses US$20.65m Earnings -US$76.70m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.40 Gross Margin -831.34% Net Profit Margin -1,137.64% Debt/Equity Ratio 5.0%
How did 0SGC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 12:48 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Arbutus Biopharma Corporation is covered by 27 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Brian Skorney Baird David Martin Bloom Burton & Co.
Show 24 more analysts 